Skip to main content

anti-tgf-beta monoclonal antibody sar-439459

Generic: Anti-TGF-beta Monoclonal Antibody SAR-439459

anti-tgf-beta monoclonal antibody sar-439459: 2 clinical trials tracked.

anti-tgf-beta monoclonal antibody sar-439459 evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-tgf-beta monoclonal antibody sar-439459, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Osteogenesis Imperfecta
Clinical Trials (2)

A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta

NCT05231668·Phase 1·SNY
Terminated

Primary endpoint: Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)

InterventionalRandomizedtriple16 targetStarted 2022-08Completion 2024-1113 sites · Australia, Canada, France, United StatesSanofi

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

NCT04643002·Phase 1/Phase 2·SNY
Recruiting

Primary endpoint: Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab

InterventionalRandomizedopen258 targetStarted 2021-01Completion 2028-0426 sites · Australia, France, Germany, Greece…Sanofi